UMMS Affiliation

Department of Neurology; Memorial Multiple Sclerosis Center, UMass Memorial Medical Center

Publication Date


Document Type



Amino Acids, Peptides, and Proteins | Biological Factors | Immune System Diseases | Nervous System Diseases | Pathological Conditions, Signs and Symptoms


Several clinical, immunological and radiological biomarkers have been shown to predict the disease course of multiple sclerosis (MS).One potential serum marker is the gMS-Classifier1, which is composed of IgM anti-Glc antibodies, namely anti-GAGA 2,3,4 and 6. Previous work demonstrated that the gMS-Classifier1 could not predict early conversion to clinically definite MS in a cohort of clinically isolated syndrome (CIS) patients, but predicted Expanded Disability Status Scale (EDSS) progression. Significance, however, was dependent on covariates, and confirmation in an independent study was required. The aim of this study was to test if the gMS-Classifier1 could predict early disability progression in a large multicenter cohort of patients with CIS or relapse-onset MS.


multiple sclerosis, biomarkers, gMS-Classifier1

Rights and Permissions

© The Author(s), 2018. Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)

DOI of Published Version



Mult Scler. 2019 Jun;25(7):1010-1011. doi: 10.1177/1352458518798048. Epub 2018 Aug 31. Link to article on publisher's site

Journal/Book/Conference Title

Multiple sclerosis (Houndmills, Basingstoke, England)

Related Resources

Link to Article in PubMed

PubMed ID


Creative Commons License

Creative Commons Attribution-Noncommercial 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License